Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9NLO

Escherichia coli Signal Peptidase I Delta 2-76 P84A in complex with lipopeptide inhibitor

Summary for 9NLO
Entry DOI10.2210/pdb9nlo/pdb
Related1b12 1kn9 1t7d 3iiq 3s04
Related PRD IDPRD_000117
DescriptorSignal peptidase I, ARYLOMYCIN A2, 1,2-ETHANEDIOL, ... (5 entities in total)
Functional Keywordssignal peptidase, membrane protein, serine-lysine catalytic dyad, inhibitor complex, hydrolase, hydrolase-inhibitor complex, hydrolase/inhibitor
Biological sourceEscherichia coli K-12
More
Total number of polymer chains4
Total formula weight57695.36
Authors
Paetzel, M.,Luo, C. (deposition date: 2025-03-03, release date: 2025-11-19, Last modification date: 2025-11-26)
Primary citationLuo, C.,Paetzel, M.
Crystal structure of Escherichia coli type I signal peptidase P84A in complex with lipopeptide antibiotic arylomycin A 2 .
J.Struct.Biol., 217:108260-108260, 2025
Cited by
PubMed Abstract: Type I signal peptidase (SPase I) is an essential membrane-bound enzyme that removes amino-terminal signal peptides from secretory proteins. Owing to its critical role in bacterial viability and its periplasmic accessibility, SPase I has emerged as an attractive target for antibiotic development. Arylomycins, a class of macrocyclic lipohexapeptide natural products, inhibit SPase I by binding to its active site. Previous studies have identified a key resistance determinant-a proline residue at the base of the substrate-binding groove (Pro84 inEscherichia coliSPase I)-which reduces arylomycin affinity. Here, we present the crystal structure of theE. coliSPase I P84A mutant in complex with arylomycin A, revealing that the introduced alanine enables an additional hydrogen bond between the enzyme backbone and the arylomycin N-terminal carbonyl, thus enhancing the affinity for arylomycins. Furthermore, a newly developed preprotein-binding assay utilizing a non-cleavable version of ProOmpA Nuclease A demonstrates that substituting SPase I Pro84 with serine or leucine disrupts substrate recognition, underscoring the delicate balance between inhibitor resistance and substrate processing. These findings reveal that residue Pro84 participates in the interaction between preprotein signal peptides and the E. coli SPase I substrate-binding groove, offering a foundation for designing next-generation arylomycin analogs with improved antibacterial potency.
PubMed: 41207487
DOI: 10.1016/j.jsb.2025.108260
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.32 Å)
Structure validation

247947

PDB entries from 2026-01-21

PDB statisticsPDBj update infoContact PDBjnumon